European Journal of Molecular & Clinical Medicine

Aim: To correlate between the severity of diabetic peripheral polyneuropathy and glycosylated hemoglobin (HbA1C) levels.
Material and method: The present prospective observational study was conducted to evaluate the type 2 DM with peripheral neuropathy patients from December 2020 to August 2022. 100 subjects having age > 18 Years, patients diagnosed for DPN by clinically (DNS >=1)/ by electro diagnostic testing (in selected cases) were included in the study. HbA1c levels were assayed using Biochemical method. Severity of DPN Categorized By Neuropathy Disability Score (NDS).
Results: Hypertension and cardiovascular disease was revealed in 14.17% and 6.67% of the subjects respectively. NDS score viz. mild, moderate and severe deficits was found among 13%, 68% and 19% of the subjects respectively. Mean HbA1c level increases along with increase in NDS score i.e., higher the deficits, more is the HbA1c.
Conclusion: It can be concluded that increased HbA1c level indicative of chronic hyperglycemia, could significantly increase the risk and quantitatively reflect the severity of polyneuropathy in diabetic patients

Diabetic peripheral neuropathy (DPN) is a common complication of both type 1 and type 2 diabetes affecting over 90% of the diabetic patients. Due to the toxic effects of hyperglycemia there is development of this problem. It is classically characterized by significant deficits in tactile sensitivity, vibration sense, lower-limb proprioception, and kinesthesia. Painful DPN has been shown to be associated with significant reductions in overall quality of life, increased levels of anxiety and depression, sleep impairment, and greater gait variability. Hence DPN is often inadequately treated, and the role of improving glycemic control in diabetes. Major international clinical guidelines for the management of DPN recommend several symptomatic treatments. First-line therapies include tricyclic antidepressants, serotonin–noradrenaline reuptake inhibitors, and anti- consultants that act on calcium channels. Other therapies include opioids and topical agents such as capsaicin and lidocaine. The objectives of this paper are to review current guidelines for the pharmacological management of DPN